valproic acid

Ligand id: 7009

Name: valproic acid

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: valproic acid

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 37.3
Molecular weight 144.12
XLogP 2.74
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Valproic acid is currently approved for the treatment of various seizure disorders, manic episodes of bipolar disorder and migraine headache. Valproic acid is, in addition, a histone deacetylase (HDAC) inhibitor and is being investigated as a treatment for HIV infection and various cancers.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of succinic semi-aldehyde dehydrogenase (ALDH5A1) may contribute to the elevated levels of cerebral and cerebellar GABA observed as a result of valproic acid administration (in animal models). ALDH5A1 is a GABA degradative enzyme. Increased levels of GABA cause neuro-inhibition and may be mechanistically linked to the drug's anticonvulsant and mood-stabilising effects. However, we have been unable to find affinity data for this drug to substantiate this proposed MMOA.

Valproic acid is also an inhibitor of Class I and II HDACs. In relation to HIV infection and the potential antiviral effects of valproic acid, HDAC1 is required for persistence of HIV in infected cells.
External links